{"id":"reboxetine-pill","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL14370","moleculeType":"Small molecule","molecularWeight":"313.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a selective norepinephrine reuptake inhibitor (NRI), reboxetine blocks the norepinephrine transporter, preventing the reabsorption of norepinephrine from the synaptic cleft. This increases norepinephrine concentration in key brain regions involved in mood regulation and attention. Unlike SSRIs, reboxetine has minimal effects on serotonin reuptake, making it a norepinephrine-selective antidepressant.","oneSentence":"Reboxetine selectively inhibits the reuptake of norepinephrine at the presynaptic neuron, increasing norepinephrine availability in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:21.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Attention deficit hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT05880342","phase":"PHASE3","title":"The Role of the Brain in Mental and Physical Fatigue","status":"RECRUITING","sponsor":"Vrije Universiteit Brussel","startDate":"2023-05-03","conditions":"Fatigue","enrollment":62},{"nctId":"NCT05133804","phase":"PHASE2","title":"Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD","status":"RECRUITING","sponsor":"University of Haifa","startDate":"2022-06-01","conditions":"Posttraumatic Stress Disorder","enrollment":53},{"nctId":"NCT05978505","phase":"PHASE2","title":"Reboxetine for Sleep Apnoea After ENT Surgery","status":"RECRUITING","sponsor":"Flinders University","startDate":"2023-08-10","conditions":"Sleep Apnea, Obstructive","enrollment":20},{"nctId":"NCT04384562","phase":"NA","title":"Studying the Role of Brain Molecules for Decision Making","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2020-12-17","conditions":"Decision Making, Healthy","enrollment":160},{"nctId":"NCT04097288","phase":"PHASE1","title":"Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2019-09-17","conditions":"Stress Urinary Incontinence, Fecal Incontinence","enrollment":24},{"nctId":"NCT04371146","phase":"NA","title":"The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2019-07-03","conditions":"Healthy","enrollment":120},{"nctId":"NCT01300364","phase":"PHASE4","title":"Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia","status":"UNKNOWN","sponsor":"Fundació Sant Joan de Déu","startDate":"2008-11","conditions":"Schizophrenia","enrollment":249}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Reboxetine Pill","genericName":"Reboxetine Pill","companyName":"Vrije Universiteit Brussel","companyId":"vrije-universiteit-brussel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reboxetine is a small molecule that inhibits the sodium-dependent noradrenaline transporter, specifically the norepinephrine transporter. It has been studied in various clinical trials for conditions such as decision making, sleep apnea, stress urinary incontinence, and fecal incontinence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}